Marker Therapeutics, Inc. Common Stock (MRKR) is a publicly traded Healthcare sector company. As of May 21, 2026, MRKR trades at $1.41 with a market cap of $23.18M and a P/E ratio of -2.33. MRKR moved +2.16% today. Year to date, MRKR is -21.23%; over the trailing twelve months it is +23.68%. Its 52-week range spans $0.81 to $5.95. Analyst consensus is buy with an average price target of $9.00. Rallies surfaces MRKR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Marker Therapeutics Posts 66% Response Rate, Secures $17M to Fund Runway Through Q4: Marker Therapeutics reported a 66% objective response rate in relapsed non-Hodgkin lymphoma with 50% complete responses in its Phase 1 APOLLO study, and expects dose expansion data in Q2 2026. The company ended 2025 with $17 million cash, funding operations through the fourth quarter of 2026.
| Metric | Value |
|---|---|
| Price | $1.41 |
| Market Cap | $23.18M |
| P/E Ratio | -2.33 |
| EPS | $-0.61 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.95 |
| 52-Week Low | $0.81 |
| Volume | 3.84K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.95M |
| Net Income | $-10.90M |
| Gross Margin | 0.00% |
2 analysts cover MRKR: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.00.